BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34324714)

  • 21. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
    Herawi M; Epstein JI
    Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.
    Leo P; Chandramouli S; Farré X; Elliott R; Janowczyk A; Bera K; Fu P; Janaki N; El-Fahmawi A; Shahait M; Kim J; Lee D; Yamoah K; Rebbeck TR; Khani F; Robinson BD; Shih NNC; Feldman M; Gupta S; McKenney J; Lal P; Madabhushi A
    Eur Urol Focus; 2021 Jul; 7(4):722-732. PubMed ID: 33941504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Akamatsu S; Terada N; Miyazawa Y; Narita S; Haba R; Sugimoto M
    Jpn J Clin Oncol; 2023 Oct; 53(10):984-990. PubMed ID: 37496400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens.
    Hollemans E; Verhoef EI; Bangma CH; Schoots I; Rietbergen J; Helleman J; Roobol MJ; van Leenders GJLH
    Histopathology; 2019 Sep; 75(3):338-345. PubMed ID: 31045262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of prostatic adenocarcinoma Gleason 5 and intraductal carcinoma of the prostate with tumor necrosis. A morphometric study.
    Acosta AM; Vormittag E; Al Rasheed MRH; Sharif A; Mon KS; Kajdacsy-Balla A; Mohapatra G
    Pathol Res Pract; 2018 Oct; 214(10):1681-1685. PubMed ID: 30195638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.
    Chaux A; Peskoe SB; Gonzalez-Roibon N; Schultz L; Albadine R; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Mod Pathol; 2012 Nov; 25(11):1543-9. PubMed ID: 22684219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
    Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
    Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with Grade Group 5 prostate cancer.
    Oufattole J; Dey T; D'Amico AV; van Leenders GJLH; Acosta AM
    Histopathology; 2023 Jun; 82(7):1089-1097. PubMed ID: 36939057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.
    Sorvina A; Martini C; Prabhakaran S; Logan JM; S-Y Ung B; Moore C; Johnson IRD; Lazniewska J; Tewari P; Malone V; Brooks RD; Hickey SM; Caruso MC; Klebe S; Karageorgos L; O'Leary JJ; Delahunt B; Samaratunga H; Brooks DA
    Pathology; 2023 Oct; 55(6):792-799. PubMed ID: 37422404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
    Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
    Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Greenland NY; Cowan JE; Zhang L; Carroll PR; Chan E; Stohr BA; Simko JP
    Prostate; 2020 May; 80(8):653-659. PubMed ID: 32220141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
    Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.
    Montironi R; Cimadamore A; Gasparrini S; Mazzucchelli R; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):685-693. PubMed ID: 29699428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer.
    Greenland NY; Cooperberg MR; Wong AC; Chan E; Carroll PR; Simko JP; Stohr BA
    Investig Clin Urol; 2022 Jan; 63(1):27-33. PubMed ID: 34983120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
    Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
    Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.